Neuropathy Treatment: What the Latest Research Says Actually Works

If you've been living with neuropathy - the numbness, tingling, burning, or shooting pain that usually starts in the feet - you may have heard the same discouraging line for years: "there's not much to do for nerve pain." That answer is quietly becoming outdated. Research published in the last year has given us a much clearer picture of what actually helps, and it's worth knowing about before you settle for "learn to live with it."

The 2025 medication update: what doctors now reach for first

In 2025, the Neuropathic Pain Special Interest Group - the international body that sets treatment guidance for nerve pain - updated its first-line recommendations. The drugs at the top of the list aren't painkillers in the traditional sense. They're medications that calm overactive nerve signaling: tricyclic antidepressants, SNRIs, and alpha-2-delta ligands like gabapentin and pregabalin.

That's worth saying plainly: for most neuropathic pain, first-line treatment is not an opioid, and opioids aren't recommended for it in the first place. These nerve-targeted medications work differently and don't carry the same addiction risk. They don't help everyone, and side effects are real - which is why the guidance also emphasizes starting low and going slow, under a clinician's supervision. But the evidence behind them is stronger than for anything else available right now.

TENS: the strongest non-drug evidence yet

The most interesting development came in April 2025, when a network meta-analysis in the Journal of NeuroEngineering and Rehabilitation pooled 15 randomized controlled trials covering 1,139 people with diabetic neuropathy. Its conclusion was striking: across all the non-invasive stimulation methods studied - brain stimulation, magnetic stimulation, and others - only one showed a significant benefit. That was transcutaneous electrical nerve stimulation, or TENS.

TENS works by delivering gentle electrical pulses through pads placed on the skin near the affected nerves. In the analysis, it meaningfully reduced pain severity and, notably, improved sleep disruption - the symptom many neuropathy patients say bothers them most. No other non-invasive technique in the review reached significance on those outcomes.

That's a genuinely useful finding. TENS is accessible, drug-free, and increasingly offered as part of a structured treatment plan rather than as a stand-alone gadget.

Why "the next big drug" hasn't arrived - yet

New isn't automatically better, and the field has had a humbling reminder. Suzetrigine, a sodium-channel blocker that won FDA approval for acute pain, failed to beat placebo for radiculopathy-related nerve pain in a phase II trial. Meanwhile, genuinely promising candidates - low-dose naltrexone, selective sodium-channel blockers, and others - are still being studied specifically for neuropathic pain.

The honest takeaway: there is no single new miracle treatment on the horizon. The gains are coming from better use of what works, earlier diagnosis, and combining approaches.

The part research can't skip: treating the cause

No treatment performs well if the underlying driver keeps damaging nerves. For diabetic neuropathy, that means tight blood sugar control. For others, it means correcting a B12 deficiency, adjusting a medication, or managing an autoimmune condition. The evidence is consistent: treating the cause is what slows progression - everything else manages symptoms.

What this means for you

The era of "nothing can be done" is over - but the era of one-size-fits-all treatment never existed. Whether you're a good candidate for nerve-targeted medication, TENS-based therapy, or a combination depends on what's actually driving your neuropathy. That's exactly why evaluation comes first.

At Forever Young LA, we assess the cause of your nerve symptoms before recommending anything, and we build a plan around the evidence and your specific situation.

Ready to find out if neuropathy treatment is right for you? Book a consultation We'll take it from there.